Resolving disease
Promoting host defense
Pioneering Resolution Biology
Thetis is a clinical-stage pharmaceutical company developing TP-317, a BLT1 agonist, as an oral therapy for inflammatory bowel disease (IBD) and solid tumor cancers.
TP-317: First-in-Class, Oral BLT1 Agonist
TP-317 activates the BLT1 receptor to promote tissue and immune homeostasis. In a Phase 1a in healthy volunteers, TP-317 was well-tolerated and demonstrated target engagement. A 12-week proof-of-mechanism study in moderate-to-severe ulcerative colitis patients will begin in 2026. TP-317 is IND-ready for Phase 1 clinical trials in patients with advanced solid tumor cancer.
Enabling Resolvin Therapy
Discovered in 2000, Resolvin E1 (RvE1) is an endogenous lipid mediator with potent pharmacology to address chronic inflammatory disorders and cancer. However, pharmaceutical development has been hampered by its poor stability. Our innovative technology overcomes this hurdle to enable development of RvE1 therapeutics.